The Evolving Strategies for Managing nAMD and DME: Empowering Managed Care Decisions for Improved Patient Outcomes

This activity was originally broadcast in conjunction with AMCP Nexus 2024.

Program Description

Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) significantly impact vision and patient quality of life. Intravitreal administration of VEGF inhibitors has been the standard for treating retinal diseases, and while effective, these therapies may be a bit burdensome for patients due to the need for frequent injections and monitoring. New and emerging treatment options may help reduce treatment limitations, and clinical emphasis has been on improving patient adherence to treatment plans through the development of longer-lasting therapies. Managed care professionals play a vital role in the treatment selection process for patients with these conditions by optimizing drug formularies and ensuring access to care while minimizing costs. This session will review the challenges of treating nAMD and DME and the potential benefits of new treatment options. With the growing number of treatment options for patients with nAMD and DME, decision-making is more complex and requires managed care professionals to carefully consider benefits, risks, and patient goals.

Target Audience: Managed care pharmacists

Type of Activity: Application
Release date: October 22, 2024
Expiration date: October 22, 2025
Learner level: Intermediate
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify the unmet needs as well as the disease and treatment burden for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
• Examine the latest efficacy, safety, and real-world data of treatments for nAMD and DME, including anti-vascular endothelial growth factor agents and emerging therapies
• Explore the value of patient-centered strategies to optimize care and reduce costs in patients with nAMD and DME

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-300-H01-P. The activity is available for CE credit through October 22, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Joshua Mali, MD, FASRS, has the following relevant financial relationships with commercial interests to disclose:

Grant/Research Support: Samsara Vision, Notal Vision

Consultant: Genentech, Eyepoint, Apellis, Iveric Bio/Astellas, Alimera Sciences, Notal Vision, Samsara Vision

Speakers Bureau: Genentech, Notal Vision

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

YuQian Liu, PharmD

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta, and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms